CTI BioPharma
223 articles about CTI BioPharma
-
Sobi completes acquisition of CTI BioPharma Corp.
6/26/2023
Swedish Orphan Biovitrum AB and CTI BioPharma Corp. announced the completion of the acquisition of CTI by Sobi through its indirect wholly owned subsidiary Cleopatra Acquisition Corp..
-
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
5/30/2023
CTI BioPharma Corp. announced that it has cancelled the 2023 Annual Meeting of Stockholders which was scheduled for June 21, 2023, and has withdrawn the proposals to have been submitted to stockholders at the Annual Meeting.
-
Sobi to Acquire CTI BioPharma
5/10/2023
CTI BioPharma announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB, a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion.
-
The acquisition provides the Swedish company with an approved JAK inhibitor for myelofibrosis, a rare bone marrow cancer that disrupts the body's normal production of blood cells.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 05, 2023
5/5/2023
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employee's acceptance of employment with the company.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2023
5/2/2023
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employee's acceptance of employment with the company.
-
CTI BioPharma Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
5/1/2023
CTI BioPharma Corp. today announced that two abstracts have been accepted for presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 11, 2023
4/11/2023
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 21, 2023
3/21/2023
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to four new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2023
3/6/2023
CTI BioPharma Corp. today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to five new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan.
-
CTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Monday, March 6, 2023
2/23/2023
CTI BioPharma Corp. today announced that its fourth quarter and full year 2022 financial results will be reported on Monday, March 6, 2023, after the close of the financial market.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 08, 2023
2/8/2023
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma to Participate in Upcoming Investor Conferences in February 2023
2/2/2023
CTI BioPharma Corp. (Nasdaq: CTIC) today announced that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2023.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 25, 2023
1/25/2023
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employee's acceptance of employment with the company.
-
CTI BioPharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/5/2023
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 20, 2022
12/20/2022
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition
12/11/2022
CTI BioPharma Corp. announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of Hematology Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022.
-
CTI BioPharma to Present at the JMP Securities Hematology and Oncology Summit
11/30/2022
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3:00 p.m. ET.
-
CTI BioPharma to Present at Upcoming November 2022 Conferences
11/8/2022
CTI BioPharma Corp. announced that management will provide a corporate overview at two upcoming investor conferences in New York and London.
-
CTI BioPharma Reports Third Quarter 2022 Financial Results
11/7/2022
CTI BioPharma Corp. reported its financial results for the third quarter ended September 30, 2022.